Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2014 r. – raport Grupy Roboczej PTHiT oraz PALG – CLL

Publication date: July–September 2014 Source:Acta Haematologica Polonica, Volume 45, Issue 3 Author(s): Tadeusz Robak , Iwona Hus , Jerzy Błoński , Krzysztof Giannopoulos , Krzysztof Jamroziak , Jacek Roliński , Piotr Smolewski , Dariusz Wołowiec Chronic lymphocytic leukemia (CLL) is predominantly a disease of the elderly, with a median age of 70 years at diagnosis. Appropriate treatment approach requires physical examination, evaluation of performance status, co-morbidities and severity of comorbid conditions, biological age, peripheral, blood count with morphologic examination. In addition, in some patients bone marrow evaluation, serum biochemistry including serum lactate dehydrogenasis and β2-microglobulin, Coombs’ test, imaging of adenomegalies, assessed either by CT scan or by the combination of chest X-ray and abdomen ultrasound should be incorporated into decision-making process with regard to intensity of treatment. In patients requiring therapy, particularly a second-line treatment, del 17p and/or p53 mutations should be also checked. Elderly and/or comorbid patients with CLL may not tolerate more aggressive approach due to high risk of unacceptable toxicity of purine nucleoside analogs, especially in combination with cyclophosphamide and rituximab. Therefore in these patients population, chlorambucil +/- rituximab is still accepted as the first-line treatment and chlorambucil remains the backbone of treatment against which the new protocols sho...

Source: Acta Haematologica Polonica - October 12, 2014 Category: Hematology Source Type: research